01-02-2017 | Original Article
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
Published in: International Journal of Clinical Oncology | Issue 1/2017
Login to get access